National Institutes of Health

Description

This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to take part in the creation of Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (SUDs). The purpose of this Funding Opportunity Announcement (FOA) is to support the creation of Laboratories with expertise and resources to conduct early clinical evaluation of potential pharmacotherapies for Substance Use Disorders (SUDs). The goal is to accelerate the clinical development of medications to treat Substance Use Disorders (SUDs) by supporting Laboratories with expertise and resources to timely and efficiently conducting FDA-defined Phase 1 and/or Phase 2 clinical trials of new or repurposed compounds to treat SUDs. the clinical development of medications to treat Substance Use Disorders (SUD) by supporting laboratories with the expertise and resources to timely and efficiently conduct early (Phase 1 or Phase 2) clinical trials of potential pharmacotherapies for SUDs.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV